<DOC>
	<DOCNO>NCT02557529</DOCNO>
	<brief_summary>72 patient head neck cancer , undergo primary treatment radiation therapy concomitant weekly cisplatin , recruit multicentre trial . Randomized 1:1 either 12-week progressive resistance training ( PRT ) program control arm , start together concomitant chemoradiotherapy ( CCRT ) Stratified centre , gender , p16-status body mass index ( BMI ) 30 . Primary endpoint difference change lean body mass ( LBM ) group endpoint reduction LBM loss intervention arm 25 % compare control . Secondary endpoint include side-effects treatment , change body composition , physical function strength , compliance PRT . Questionnaires QoL , diet , voluntary exercise work affiliation also register . Blood sample explorative analysis draw optional muscle biopsy draw proteomics analysis histological analysis .</brief_summary>
	<brief_title>Progressive Resistance Training Head Neck Cancer Patients During Concomitant Chemoradiotherapy</brief_title>
	<detailed_description>The PRT program start onset radiotherapy . The program consist 7 exercise train machine involve major muscle group body . The program previously find successfully restore loss lean body mass ( LBM ) head neck cancer patient post-treatment . A group base approach use facilitate social motivate training environment patient . A pilot study ( NCT02068950 ) show feasibility PRT CCRT . In addition baseline data ( height , tumor stage , performance status , etc ) , follow parameter register : Weight , patient report side effect , well questionnaire amount physical activity food intake . Physical function strength test baseline , course chemoradiotherapy end 12-week PRT programme , 6 12 month follow-up . DXA scan body composition perform use Lunar iDXA ( GE Healthcare ) . Blood sample draw regular interval 12 week follow-up . Patient report quality life ( EORTC Quality Life Questionnaire ( QLQ ) -C30 QLQ-H &amp; N35 ) also register . Muscle biopsy take three time : baseline , treatment 12-weeks PRT . Study duration expect 18 month additional 12 month follow-up .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Patients biopsy verify head neck squamous cell carcinoma refer primary curatively intend treatment . Candidates concomitant chemoradiotherapy ( 2Gyx3334 ; 6F/W ; weekly cisplatin 40mg/m2 , max . 70 mg/weekly ) accord Danish Head Neck Cancer Group ( DAHANCA ) guideline ( T14 , N13 , M0 ) Performance status 01 At least 18 year age . BMI 20.5 diabetes corticosteroid treatment disease Tonsillectomy within last week inclusion . hemoglobin 6 mmol/l leucocytes 2.5 x 10^9 /l thrombocyte 50 x 10^9 /l comorbidities , social , familial geographical condition , could compromise attendance result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Concomitant chemoradiotherapy</keyword>
	<keyword>Exercise Training</keyword>
	<keyword>Progressive Resistance Training</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Lean Body Mass</keyword>
	<keyword>Body Composition</keyword>
</DOC>